Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER

A pliable ERα cistrome evades therapy

The transcription factor oestrogen receptor alpha (ERα) has long been targeted for therapeutic benefit in cancer, but drug resistance can emerge through a multitude of mechanisms. A study now reveals how the ERα cistrome can become reprogrammed to confer resistance to tamoxifen in breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: A reprogrammed ERα cistrome that bypasses tamoxifen therapy in breast cancer.

References

  1. Darnell, J. E. Jr. Nat. Rev. Cancer 2, 740–749 (2002).

    Article  CAS  Google Scholar 

  2. Bhagwat, A. S. & Vakoc, C. R. Trends Cancer 1, 53–65 (2015).

    Article  Google Scholar 

  3. Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Cancer Cell 37, 496–513 (2020).

    Article  CAS  Google Scholar 

  4. Bi, M. et al. Nat. Cell Biol. https://doi.org/10.1038/s41556-020-0514-z (2020).

  5. Ross-Innes, C. S. et al. Nature 481, 389–393 (2012).

    Article  CAS  Google Scholar 

  6. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. Nat. Genet. 43, 27–33 (2011).

    Article  CAS  Google Scholar 

  7. Fu, X. et al. Proc. Natl. Acad. Sci. USA 113, E6600–E6609 (2016).

    Article  CAS  Google Scholar 

  8. Malorni, L. et al. Mol. Cancer Res. 14, 470–481 (2016).

    Article  CAS  Google Scholar 

  9. Lupien, M. et al. Genes Dev. 24, 2219–2227 (2010).

    Article  CAS  Google Scholar 

  10. Hiscox, S. et al. Int. J. Cancer 118, 290–301 (2006).

    Article  CAS  Google Scholar 

  11. Jakacka, M. et al. J. Biol. Chem. 276, 13615–13621 (2001).

    Article  CAS  Google Scholar 

  12. Chen, D. et al. Mol. Cell 6, 127–137 (2000).

    Article  CAS  Google Scholar 

  13. Jeselsohn, R. et al. Cancer Cell 33, 173–186.e5 (2018).

    Article  CAS  Google Scholar 

  14. Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L. & Chandarlapaty, S. Nat. Rev. Cancer 18, 662 (2018).

    Article  CAS  Google Scholar 

  15. Guan, J. et al. Cell 178, 949–963.e18 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christopher R. Vakoc.

Ethics declarations

Competing interests

C.R.V. has received funding from Boehringer Ingelheim and Syros Pharmaceuticals and is an advisor to KSQ Therapeutics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, X.S., Vakoc, C.R. A pliable ERα cistrome evades therapy. Nat Cell Biol 22, 619–620 (2020). https://doi.org/10.1038/s41556-020-0528-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41556-020-0528-6

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer